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Background: Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only
three cases are reported in children, all of them with hemophilia A.
Case presentation: We present unique case of patient with hemophilia B and high titer inhibitors to coagulation
FIX, who developed severe renal damage due to thromboembolic event during rFVIIa therapy, associated with
unsuspected renovascular anomalies.
Conclusion: Caution is necessary if hematuria B requires administration of rFVIIa. US color doppler renal imaging
before and after drug administration should be sufficient as an early warning.Background
Recombinant factor VIIa (rFVIIa, Novoseven®) has been
shown to induce hemostasis in hemophilia patients with
inhibitors against factor VIII or factor IX independent
of factor VIII/factor IX. rFVIIa initiates hemostasis by
forming a complex with tissue factor (TF) exposed as a re-
sult of vessel wall injury. Pharmacologic doses of rFVIIa
can enhance thrombin generation. Recombinant activated
factor VII (rFVIIa, Novoseven®) is in regular clinical use in
haemophilia B patients with high-titer inhibitors to coagu-
lation factor IX (FIX) since 1996 [1]. Potential adverse
event of rFVIIa therapy is pathological blood clotting.
However, when rFVIIa is used in labeled indications such
adverse event is rare and did not appear to be dose-
related. The incidence of serious thromboembolic events
after treatment with rFVIIa in hemophilia patients with
inhibitors appears to be much less than 1%, with only
three cases reported in children, all of them with he-
mophilia A and predisposing factors [2-4].
We present the patient with hemophilia B and high
titer inhibitors to coagulation FIX who was treated with* Correspondence: danko.milosevic@zg.t-com.hr
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unless otherwise stated.rFVIIa for severe life-threatening hematuria. Although
hematuria was successfully treated, renal thromboem-
bolic adverse event associated with unsuspected vascular
anomalies resulted in severe renal damage. To our know-
ledge, this is the first case of tromboembolic event con-
nected with rFVIIa therapy with this set of symptoms
presented exclusively on kidney with underlying vascular
anomalies. The second normal kidney was fully spared.
Case presentation
A seven-year-old Croatian boy with hemophilia B with
high-titer inhibitors to coagulation FIX was admitted at
our institution with severe hematuria. The parents de-
nied trauma, any medication or infection. He was previ-
ously treated with rFVIIa, mostly for bleeding affecting
limb joints. Clinical, diagnostic and medication follow-
up is shown in Figure 1. Painless hematuria was treated
during the first three days with only symptomatic ther-
apy consisting of intravenous hyperhidration and bed
rest. On the fourth and fifth day, a fall in hemoglobin
level was noticed and single daily dose of 285 μg/kg
rFVIIa was administered intravenously in a 10–20 mi-
nute interval on both consecutive days. Despite the ther-
apy, a life-threatening condition developed on the sixth
day with rapid fall of red blood cells count (RBC) accom-
panied with massive hematuria. The total rFVIIa dose wasal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical, diagnostic and medication follow up. Blue shaded areas indicate days of activated recombinant factor VII (rFVIIa) therapy.
Orange boxes indicate times of renal US. WNL - within normal limits, *1 - left pyelon dilation. Inhomogenous content compatible with pyelon
clotting. Yellow box indicate time of renal Doppler, WNL - within normal limits. Purple boxes indicate times of renal scintigraphy, *2 – functional
abnormality of the left kidney, WNL - within normal limits. Brown box indicates time of abdominal MSCT, *3 – renovascular anomalies of
left kidney.
Milošević et al. BMC Pediatrics 2014, 14:315 Page 2 of 4
http://www.biomedcentral.com/1471-2431/14/315subsequently increased by administration every three
hours, four times in total with each amount of 105 μg/kg.
The treatment successfully stabilized RBC count and re-
duced hematuria. As hematuria, although reduced, con-
tinued, for the following two days the child received
additional rFVIIa (once daily 285 μg/kg). On the fourth
day of rFVIIa therapy the patient first time complained of
left lumbar colic pain, and visible blood clots in urine ap-
peared. The rFVIIa therapy was discontinued. Only hy-
perhydration and occasional spasmolytic therapy were
continued. From the eleventh day, hematuria was only
microscopic. In the course of the disease several ultra-
sound (US) examinations were performed. Initially, nor-
mal US showed, coincidently with renal colics, enlarged
left kidney with hyperechogenic inhomogenous paren-
chyma with partial loss of corticomedulary differentiation
and dilated pelvicaliceal system with hyperechogenic inho-
mogenous content compatible with clots. Only a vascular
bed over the left kidney without visualization of the paren-
chyma with practically afunctional renographic curve was
found on 99mTc-DTPA (Diethylene Triamine Pentacaetic
Acid) renal scintigraphy (Figure 2A). In the first minutes
of 99mTc-MAG3 (Mercaptoacetyltriglycine) scintigraphy,
the left kidney was very pale becoming increasingly bettervisualized later (Figure 2B). Renographic curve showed
obstruction over the third phase of the renogram. MSCT
(multi-slice computer tomography) renal angiography re-
vealed severe left kidney damage with 3 independent un-
obstructed arteries; two of them starting regularly, the
third beginning caudally at the approximate position of
the lower pole of the left kidney. The same kidney had 2
veins who communicated with each other, the first had
circumaortal course with vascular convolutes and the sec-
ond (accessory) showed retroaortal course supplying the
lower pole of the kidney (Figure 3). Nine months later
renal scintigraphy was repeated. The finding was normal.
Conclusion
The risk of clot formation is low even if rFVIIa was
given in higher doses (>300 mcg/kg BW) [5,6]. But the
treatment with high doses of rFVIIa on an off-label basis
significantly increases the risk of arterial but not venous
thromboembolic events among the elderly [7]. In the lit-
erature we found a report of a woman with Glanzmann
Thrombasthenia with haematuria and clotting in renal
pelvis after rFVIIa administration. In this case, the major
reason for rFVIIa administration was intraoperative bleed-
ing, during laparotomy for pelvic inflammatory disease. It
Figure 2 Renal imaging in posteroanterior position (R = right kidney, L = left kidney). A. 99mTc-DTPA renal scintigraphy shows vascular bed
over the left kidney without visualization of the parenchyma with practically afunctional renographic curve of the same kidney. B. 99mTc-MAG3
scintigraphy shows very pale left kidney becoming increasingly better visualized later. Renographic curve of the left lidney shows obstruction over
the third phase of the renogram.
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kallikrein" system and that leads to increased clotting [8].
Our patient had multiple renal vascular anomalies.
Multiple renal arteries are not uncommon. Various re-
ports estimate its incidence up to 32%, usually on the
right side with very rare occurrence of triple arteries
supplying one kidney [9-12]. Anatomical variations of
multiple renal veins are less common with incidenceranging between 0.8 and 6% [13]. Both anomalies occur
far more commonly on the right side [9,13,14]. Anomal-
ies occurring in both arteries and vein together are ex-
tremely rare. To our knowledge, this is the first report of
combination of both multiple arterial and vein kidney
anomalies of one kidney while the other kidney had nor-
mal circulatory system. As we did not exceed recom-
mended rFVIIa dosage and as right kidney was spared,
Figure 3 Multi-slice computer tomography (MSCT) renal
angiography of both kidneys in anteroposterior position shows
severe left kidney damage (arrow) with 3 independent
unobstructed arteries; two of them starting regularly, the third
beginning caudally at the approximate position of the lower
pole of the left kidney. (R = right kidney).
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boembolic incident of the left kidney is a reasonable as-
sumption. According to radionuclide examinations the
main site of lesion and clotting event was intrarenal vas-
cular bed, primarily in glomerular region, while tubular
region was less affected. Renal damage secondary to pelvi-
caliceal obstruction is less likely.
Such an extremely rare troboembolic event in patients
with hemophilia B certainly do not compromise safe ad-
ministration of rFVIIa. However, caution is necessary if
hematuria requires administration of rFVIIa. US color
doppler renal imaging before and after drug administra-
tion should be sufficient as an early warning.Consent
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